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Abstract:  Background and Hypothesis: Although the biological underpinnings of immediate and protracted trauma-
related responses are extremely complex, 40 years of research on humans and other mammals have demonstrated that 
trauma (particularly trauma early in the life cycle) has long-term effects on neurochemical responses to stressful events. 
These effects include the magnitude of the catecholamine response and the duration and extent of the cortisol response. In 
addition, a number of other biological systems are involved, including mesolimbic brain structures and various neuro-
transmitters. An understanding of the many genetic and environmental interactions contributing to stress-related responses 
will provide a diagnostic and treatment map, which will illuminate the vulnerability and resilience of individuals to  
Posttraumatic Stress Disorder (PTSD).  
Proposal and Conclusions:  We propose that successful treatment of PTSD will involve preliminary genetic testing   
for specific polymorphisms. Early detection is especially important, because early treatment can improve outcome. When 
genetic testing reveals deficiencies, vulnerable individuals can be recommended for treatment with “body friendly”   
pharmacologic substances and/or nutrients. Results of our research suggest the following genes should be tested:   
serotoninergic, dopaminergic (DRD2, DAT, DBH), glucocorticoid, GABAergic (GABRB), apolipoprotein systems 
(APOE2), brain-derived neurotrophic factor, Monamine B, CNR1, Myo6, CRF-1 and CRF-2 receptors, and neuropeptide 
Y (NPY). Treatment in part should be developed that would up-regulate the expression of these genes to bring about a 
feeling of well being as well as a reduction in the frequency and intensity of the symptoms of PTSD. 
Keywords: Post-traumatic Stress Disorder (PTSD), genes and environment, neurotransmitters, Reward Deficiency Syndrome 
(RDS).  
BACKGROUND 
  Post-Traumatic Stress Disorder (PTSD) is an anxiety 
disorder associated with exposure to a traumatic event out-
side the range of usual human experience, e.g., severe acci-
dents, intense physical or sexual abuse, life-threatening 
medical conditions, combat, and natural disasters [1]. Com-
mon life events such as bereavement, chronic illness, and 
divorce rarely produce PTSD. The diagnosis of PTSD re-
quires the presence of symptoms in each of three clusters 
including: re-experiencing the traumatic event through intru- 
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sive memories, flashbacks, and nightmares; avoidance and 
affective numbing; and hyperarousal (Fig. 1). PTSD is a 
complex heterogeneous biopsychosocial disorder, and the 
stressors that produce PTSD are usually accompanied by 
intense fear, terror, and an overwhelming sense of helpless-
ness [2]. Although the symptoms of PTSD can interfere with 
the ability to live a normal life and maintain normal relation-
ships, its underlying pathophysiology remains ambiguous, 
despite sophisticated brain-imaging techniques and new ge-
netic knowledge. 
  Psychological symptoms after trauma may include hyper 
vigilance and poor concentration. Flashbacks can occur con-
sisting of images, sounds, smells, and feelings, causing the 
sufferer to lose touch with reality and repeatedly re-
experience the traumatic incident. These often are triggered 
by ordinary occurrences such as a door slamming or the 
backfiring of a car. Furthermore, other symptoms such as 
insomnia, and an exaggerated startle response are common. 336    Current Neuropharmacology, 2010, Vol. 8, No. 4  Bowirrat et al. 
Individuals with PTSD often re-experience the alarm phase 
response through their dreams and intrusive vivid recollec-
tions [2]. The symptoms often merge into anticipatory stress 
responses as the victims’ experience simultaneously mourn-
ing and fear [3].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Characteristics of PTSD. 
  Untreated PTSD causes significant disability and sub-
stantially increases medical utilization. It is well established 
that there is significant comorbidity with mood and anxiety 
disorders as well as Substance Use Disorder (SUD) [1, 4-6]. 
PTSD seems to affect all aspects of a person’s being, includ-
ing body, mind, and spirit. Traumatic stressful experiences 
are stored in memory, perhaps in a cumulative manner along 
with other such life experiences, and the accumulation of 
traumatic life experiences can lead to increased vulnerability 
and decreased resiliency to further trauma [5]. Additionally, 
there are likely specific gene-environmental interactions that 
influence the vulnerability or resiliency to PTSD [7].  
Historical Perspective 
  Historically, symptoms associated with PTSD were re-
ported as far back as 1900 BC by an Egyptian physician who 
described hysterical reactions to trauma [8]. About 15 centu-
ries later, Hippocrates proposed a homeostasis theory to ex-
plain illness. That is, a stress reaction often results from the 
disruption of the balance or homeostasis of a system [9, 10]. 
The situation causing the stress reaction is defined as the 
"stressor". However it is the stress reaction and not the stres-
sor that actually jeopardizes the homeostasis [5, 11]. Recent 
evidence suggests that post-traumatic stress responses result 
from a chemical imbalance of neurotransmitters. This seems 
to agree with the older views whereby stressful responses are 
tied to the homeostasis theory. Hysteria was also related to 
"traumatic reminiscences" a century ago [12]. At that time, 
Sigmund Freud's pupil, Kardiner described what later be-
came recognized as PTSD symptoms [13].  
  PTSD has been recognized as a distinct psychiatric dis-
order since 1980. It is relatively common, with a lifetime 
prevalence of approximately 8% in the general population 
[1]. PTSD is often chronic, producing symptoms for at least 
one year in 50% of cases [5, 14]. Unfortunately, in many 
cases, these symptoms persist much longer [14, 15]. Treat-
ment approaches to PTSD include individual therapy (cogni-
tive, psychodynamic, or behavioral), group therapy, and 
medications such as antidepressants, anxiolytic drugs, and 
nutraceuticals [2, 16]. The treatment of PTSD is extremely 
challenging, requiring many years of therapy with variable 
results. Therefore, genetic screening for vulnerability and 
resilience may offer an important option for the prevention 
of PTSD and the amelioration of symptoms. 
Symptoms of PTSD 
  The three main clusters of symptoms that clinicians look 
for when diagnosing PTSD are re-experiencing, avoidance, 
and hyper-arousal (Fig. 1) [1, 2, 17]. 
 Re-experiencing  symptoms include intrusive memories of 
the traumatic event, recurrent distressing dreams about the 
traumatic event, and acting or feeling as if the traumatic 
event is reoccurring. Mental and physical distress often oc-
curs when reminded of the traumatic event (e.g., on the anni-
versary of the traumatic event). Nightmares occur commonly 
in those suffering from PTSD. These nightmares can be 
frightening or highly emotional and are associated with dis-
turbed sleep and daytime hyper-arousability. People with 
PTSD report awakening from dreams that involve reliving 
the trauma. The frequency of PTSD nightmares increases 
with the severity of the trauma. Unfortunately, these night-
mares can persist long after the traumatic experience, and 
sometimes occur indefinitely [18].  
  The physiological symptoms following these frightening 
memories or nightmares can manifest as headaches, gastroin-
testinal complaints, immune system dysfunction, and chest 
pain. PTSD victims have an increased incidence of infections 
such as hepatitis and tuberculosis, muscle and skeletal dis-
eases, hypertension, fibromyalgia, and circulatory disorders 
such as cerebrovascular disease, coronary artery disease, and 
hypertension [19, 20].  
 Avoidant  symptoms are unconscious possibly biophysical 
mechanisms that help to avoid any associations with the trau-
matic event. These symptoms manifest as emotional 
“numbing” of the sufferer’s general response to people and 
events. Avoidant symptoms often include avoiding thoughts, 
feelings, people, or situations associated with the traumatic 
event, an inability to recall aspects of the traumatic event, 
reduced interest or participation in significant activities, feel-
ing disconnected from others, stress, showing a limited range 
of emotion, and having a foreshortened sense of future (e.g., 
not expecting to have a normal life span, marriage or career) 
[21-24].  
  Symptoms of increased arousal may be similar to symp-
toms of anxiety or panic attacks. Increased arousal symptoms 
include being easily startled, difficulty concentrating, exag-
gerated watchfulness and wariness, irritability or outbursts of 
anger, and difficulty falling or staying asleep [25]. Neuro-psychopharmacogenetics and Neurological Antecedents  Current Neuropharmacology, 2010, Vol. 8, No. 4    337 
THE NEUROCHEMISTRY OF PTSD 
  In PTSD there are a number of systems that get activated 
for the purpose of survival (Fig. 2). These include neuro-
transmitters such as dopamine, norepinephrine, epinephrine, 
opioid peptides, serotonin, GABA (gamma-aminobutyrate), 
glutamate, and acetylcholine, which are implicated in many 
psychological disorders. Additionally, there is evidence that 
neuropeptides such as the endorphins, somatostatin, vaso-
pressin, and oxytocin play an important role. It is also likely 
that disruption occurs in the hypothalamic-pituitary-adrenal 
(HPA) axis [26]. The HPA system is activated by stressful 
stimuli, and the disruption that occurs with PTSD can be 
conceptualized as a kind of “false alarm”. There is evidence 
that dysfunction of the HPA system may produce hippocam-
pal damage manifested as impaired memory [23]. It is hy-
pothesized that a number of medications, such as selective 
serotonin reuptake  inhibitors (SSRIs) may help to reverse 
neurochemical dysfunction in PTSD. It is as if these agents 
switch off many of the false alarms that characterize this 
condition (Figs. 3 and 4).  
  There is increasing evidence that sensitization and ge-
netic defects of neurochemical systems are crucial patho-
physiological characteristics of PTSD as evidenced by neu-
roimaging studies and genotyping [27,28]. The resultant sen-
sitization may affect attention and decision-making and acti-
vate motor adaptive systems. Other systems are activated to 
counteract the crisis response. Once the danger has passed 
these neurochemical systems normalize, and homeostasis is 
restored. It has been proposed that two neuropeptides that are 
intimately involved in this mechanism are Neuropeptide-Y 
and galanin [29].  
Serotinergic Pathways 
 Serotonin is a neurotransmitter synthesized both in the 
central nervous system and in the gastrointestinal tract. It is 
believed to play an important role in depression, bipolar dis-
order, anxiety disorders, obsessive compulsive disorder, 
sexuality, appetite, sleep as well as pain. Serotonin helps to 
fight hunger, ameliorate depression and obsessive-
compulsive symptoms, decrease pain in both fibromyalgia 
and migraine headaches, and promote sleep and weight loss. 
It was initially identified as a vasoconstrictor substance that 
increases tone in blood vessels hence the name "serotonin". 
Serotonin 5-hydroxytryptamine (5-HT) is synthesized from 
the amino acid tryptophan. 
  Taken orally, serotonin does not pass through the blood-
brain barrier, and thus has no effect on serotonin levels in the 
brain. However, the amino acid tryptophan is capable of 
crossing the blood-brain barrier. Tryptophan is available as a 
dietary supplement although its ability to increase brain sero-
tonin is still the subject of research and debate [16]. A vari-
ety of psychiatric medications increase brain serotonin lev-
els. These include the monoamine oxidase inhibitors 
(MAOIs), tricyclic antidepressants (TCAs), and the selective 
serotonin re-uptake inhibitors (SSRIs). The MAOIs prevent 
the breakdown of serotonin and therefore increase its con-
centrations in the brain. However, MAOI therapy is associ-
ated with many adverse drug reactions and patients must 
follow a strict diet to avoid the hypertensive crisis that can be 
triggered by foods high in tyramine. Tricyclic antidepres-
sants increase synaptic serotonin by inhibiting the re-uptake 
of both serotonin and norepinephrine. Like the MAO inhibi-
tors, they have many side effects. More recently SSRIs have 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Neurochemical and hormonal responses in PTSD. 338    Current Neuropharmacology, 2010, Vol. 8, No. 4  Bowirrat et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Legend: Summary of Neurobiology of PTSD. 
•  Abnormalities in the sympathetic branch  
•  Severe stress causes dysregulation of locus coeruleus causing hypersensitivity to external stimuli 
•  Studies of combat veterans vs. non-combat veterans 
•  Differences in combat veterans 
  Increased heart rate and anxiety during combat-related stimuli 
•  Increased urinary excretion of norepinephrine in PTSD patients 
•  Abnormalities of the Hypothalamic Pituitary Adrenal Axis (HPA) 
•  In acute/chronic stress and major depression: 
  Cortisol levels are increased 
•  In PTSD, sensitization of HPA occurs 
  Cortisol levels are chronically decreased 
  Patients with PTSD show lower cortisol levels up to 50 years after initial trauma 
•  Lower cortisol levels immediately following trauma can be a risk factor for developing PTSD at a later date 
•  Hippocampus 
  MRI measurements have shown it to be smaller in patients with PTSD 
  Correlates with severity of traumatic exposure, cognitive deficits, and PTSD symptoms 
•  Functional neuroimaging while stimulating with traumatic material has shown: 
  Hyperactive amygdala 
  Anterior paralimbic regions are activated 
  Decreased activity in anterior cingulate cortex 
  Decreased blood flow to the hippocampus 
•  All this goes to show that in the model of PTSD 
  Amygdala and related structures are overactive 
•  Also known as “ hot and emotional” memory system 
  Hippocampus and anterior cingulate cortex is underactive 
•  Also known as “cool and cognitive” memory system Neuro-psychopharmacogenetics and Neurological Antecedents  Current Neuropharmacology, 2010, Vol. 8, No. 4    339 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). PTSD and putative resilience mechanisms. The sympathetic nervous system (SNS) responds to stressful events by increasing heart 
rate and blood pressure and by suppressing digestion. Additionally, the noradrenergic system often is dysregulated in PTSD. When the SNS is 
strongly activated, NPY, Galanin, and norepinephrine are released to maintain SNS activity within an optimal activation range. The overall 
net hyperactivity effects of norepinephrine depend on the balance between norepinephrine, NPY, and Galanin. This supports the view that 
stress resilience seems to be associated with an ability to keep the HPA-axis and norepinephrine activity within an optimal range during stress 
exposure. 
•  Highly resilient operations soldiers tend to have high level of NPY. 
•  In contrast, Veterans diagnosed with PTSD have low level of NPY. 
•  Negative correlation has been found between DHEA and PTSD symptoms. 
•  Positive correlation has been found between DHEA/Cortisol ratio and performance among Special Forces soldiers during high stress 
training. 
•  DHEA + Allopregnalolone = Resilience to stress by helping terminate HPA activation and preventing harmful effect of glucocorticoids.  
 
been developed. These have fewer side effects, drug interac-
tions and are less toxic in the event of overdose. 
  Deficiency, or in some instances, excessive ingestion of 
certain vitamins and minerals can lead to altered serotonin 
levels through disruption of production or reuptake. Exces-
sive increases in serotonin levels can produce a dangerous 
condition known as "Serotonin syndrome". The symptoms of 
serotonin syndrome may range from headaches, dizziness 
and vomiting, and progress to coma and cardiovascular col-
lapse. 
  A number of studies suggest serotonergic involvement in 
PTSD. For example serotonin appears to play an important 
role in fear conditioning [30] and in stress-induced corticos-
teroid release [31]. Furthermore, in clinical studies, com-
pared with controls, although those suffering from PTSD 
were shown to have greater affinity for paroxetine binding 
sites, they had a reduced number of binding sites. In addi-
tion, there was a relationship between pre-treatment paroxet-
ine binding and clinical response to fluoxetine treatment [32-
34]. Also, m-chlorophenylpiperazine (m-CPP), a serotonin 
agonist, provoked PTSD symptoms in patients with the dis-
order [35]. Finally, clinical overlaps between PTSD and de-
pression, anxiety, impulsivity and aggression also suggest 
that serotonergic agents may be helpful in the treatment of 
this disorder [36]. 
Catecholamine Pathways 
 Catecholamines are chemical compounds derived from 
the amino acid tyrosine that act as neurotransmitters. High 
catecholamine levels in blood are considered markers for 
stress. Catecholamines cause physiological changes that help 
prepare the body for physical activity, e.g., the fight-or-flight 
response.  
  The catecholamines include compounds such as epineph-
rine (adrenaline), nor-epinephrine (noradrenaline), and do-
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adrenal medulla, and nor-epinephrine is also secreted by 
some nerve fibers. These substances prepare the body to 
meet emergencies such as cold, fatigue, and shock.  
  Adrenaline (epinephrine) acts as a neurotransmitter in the 
central nervous system and as a hormone in the blood circu-
lation. It increases heart rate and stroke volume, dilates the 
pupils, and constricts arterioles in the skin and gut while 
dilating arterioles in leg muscles. It elevates blood sugar 
level by increasing the breakdown of glycogen and lipids.  
 Noradrenaline  (norepinephrine) is primarily a peripheral 
sympathetic nervous system (SNS) neurotransmitter. In the 
brain, norepinephrine facilitates the formation of long-term 
memory and may preferentially facilitate the encoding of 
traumatic memory. It increases attention and may decrease 
impulsiveness. Along with epinephrine, norepinephrine   
plays an important role in the fight-or-flight response, by 
activating the SNS to increase heart rate, release energy from 
fat, and increase muscle readiness. Clinically, epinephrine is 
used to stimulate heart rate and contractility, as a pulmonary 
bronchodilator and to reduce intra-ocular pressure in   
glaucoma.  
 Dopamine is an intermediate in the synthesis of epineph-
rine. It has been shown that a deficiency in this neurotrans-
mitter dopamine may result in difficulty coping with stress-
ful conditions [37]. There is evidence that during the stress-
ful events the neuronal levels of dopamine are depleted and 
when challenged with a dopamine agonist like cocaine an 
exaggerated response (sensitization) occurs in forebrain 
pathways. In addition, patients with PTSD sometimes dem-
onstrate symptoms of hyper-vigilance and even paranoia that 
are likely to be mediated by the dopamine system [38]. 
Opioid Pathways 
  The opioid system is involved in the release of dopamine 
in the nucleus accumbens [39] and also appears to play an 
important role in trauma by acting as an endogenous “pain-
killer” [24]. As in the serotonergic system, the opioid system 
may become sensitized, with less intense shock producing 
subsequent analgesia. Not surprisingly, patients with PTSD 
often favor opioid substances of abuse [24, 39]. There is evi-
dence that the opioid antagonist naloxone may reverse the 
analgesia induced by exposure to combat films. Moreover it 
is well known that stimulation of dopamine D2 receptors in 
the nucleus accumbens inhibits pain suggesting that the 
opioids are not working in isolation [40].  
 Endorphins are endogenous opioid polypeptide com-
pounds. They are produced by the pituitary gland and the 
hypothalamus during strenuous exercise, excitement, pain, 
and orgasm,
 and like exogenous opioids such as morphine, 
fentanyl, and oxycodone produce analgesia and a sense of 
well being. Endorphins work as natural pain relievers, the 
effects of which may be enhanced by other medications as 
well as other drugs of abuse [41]. Endorphins are produced 
in response to stressful conditions and pain. They have been 
suggested as modulators of the so-called "runner's high" that 
athletes achieve with prolonged exercise [39]. At least 20 
types of endorphins are known to exist. They are produced in 
the brain (primarily the hypothalamus and pituitary) and like 
exogenous opioids reduce our perception of pain. There is 
evidence that suggests that addiction to exercise, and possi-
bly “thrill seeking behavior”, gambling etc, may produce an 
increase in dopamine and endogenous opioids, followed by 
down regulation in receptor density and changes in transport 
that result in a dependency on these activities, and symptoms 
of physical withdrawal upon cessation [42]. In addition to 
decreased feelings of pain, secretion of endorphins leads to 
feelings of euphoria, modulation of appetite, release of sex 
hormones, and enhancement of the immune response. En-
dorphin release varies among individuals. For example, two 
people who exercise at the same level or suffer the same 
degree of pain will not necessarily produce similar levels of 
endorphins. Sex and even certain foods, such as chocolate 
may increase endorphins. Furthermore, some studies have 
suggested that many of the positive effects produced by acu-
puncture, massage therapy, meditation, UV light, laughter 
and even the placebo effect may be mediated through endor-
phin release. Recently it has also been demonstrated that the 
release of endogenous opioids is associated with PTSD [24]. 
Glucocorticoids 
 Cortisol is a steroid made in the adrenal glands is neces-
sary in the functioning of almost every part of the body. It is 
the “stress hormone” produced in response to stressful condi-
tions, both physical (illness, trauma, surgery, or temperature 
extremes) and psychological. It antagonizes insulin to pro-
mote the breakdown of carbohydrates, fatty acids, and pro-
teins in order to produce the energy needed to respond to a 
potentially life threatening situation and ensure that the brain 
receives adequate energy resources. In the early stages of 
adrenal stress, cortisol levels will be elevated during the day 
and continue rising in the evening. Later, cortisol levels may 
rise and fall unevenly as the body struggles to balance itself 
against the effects produced by stressors such as caffeine, 
carbohydrates and vigorous exercise. In the middle stage, 
levels are abnormal and are especially elevated at night. In 
the advanced stages of adrenal dysregulation produced by 
prolonged stressful conditions, the adrenals may become 
exhausted from overwork, resulting in subnormal cortisol 
levels (hypoadrenia). Clinically, adrenal dysfunction may 
only be evident in its extreme stages e.g. Cushing’s disease 
or Addison’s disease.  
  Sustained high cortisol levels may produce many adverse 
effects. For example, destruction of healthy muscle and bone 
can occur. Healing and cell replacement can be delayed. Me-
tabolism can be impaired resulting in increased blood sugar, 
diabetes, increased abdominal fat, heart disease, and sup-
pressed endocrine and immune function. By-products of cor-
tisol depress brain activity and produce sedation. Cortisol 
itself can block serotonin, possibly producing or contributing 
to feelings of depression. Furthermore, adrenal dysfunction 
may be a factor in many other related conditions, including 
fibromyalgia, hypothyroidism, chronic fatigue syndrome, 
arthritis, and menstrual difficulties. Adrenal fatigue may also 
produce insomnia, and daytime somnolence. Long-term ex-
posure to cortisol may produce hippocampal damage result-
ing in impaired learning as well as mood dysregulation. 
Conversely, short-term exposure of cortisol may actually 
help to implant succinct "flashbulb memories". In addition 
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age other parts of the brain that regulate emotions, impulsive 
behavior, arousal, and attention.  
  Cortisol excess can produce overt physical changes that 
are easy to detect. These include high blood sugar, weight 
gain, hypertension, and dementia. The effect of elevated cor-
tisol on mental function is subtler and occurs at lower levels. 
These levels are frequently abnormal in patients with mood 
disorders. This suggests that cortisol may affect as well as be 
affected by one’s mental state.  
  Normally when cortisol is present in excessive amounts, 
a negative feedback system is set into place. High levels of 
cortisol inhibit the production of hypothalamic Corticotropin 
Releasing Factor (CRF), which results in feedback inhibition 
of adrenal cortico-trophic hormone (ACTH) secretion from 
the pituitary. However, animal studies suggest that this feed-
back system can break down in response to chronic stress. 
Finally, in a recent study, the administration of exogenous 
cortisol to elderly PTSD patients resulted in increased glu-
cose brain metabolism [43]. 
  Alterations in neurotransmitter and hormone activity in-
volving serotonin, natural opiates, catecholamines, and corti-
sol result in the wide range of objective and subjective PTSD 
symptoms [44]. The intrusive symptoms of PTSD (sudden 
and frightening thoughts, memories, flashbacks, and night-
mares) have been linked to high levels of CRF [45]. An ele-
vation of CRF may be conceptualized as an ignition switch 
for the stress responses. This activation and the subsequent 
release of epinephrine may have a direct effect on the forma-
tion of memories. The avoidance cluster of PTSD symptoms 
(emotional numbing, sleep disturbances, depression, and the 
use of “escape” drugs such as alcohol and illicit substances) 
have been linked to elevated levels of endogenous opioids, 
which are produced in the alarm phase to temporarily mask 
pain. The hyper-arousal group of symptoms (anxiety disor-
ders, irritability, anger outburst, hyper-vigilance, dizziness, 
sudden startle reflex, and sometimes feelings of intense sur-
vivor guilt) has been linked to exaggerated CRF levels and 
heightened SNS activity.  
Conjectured Neurotransmitters and Treatment Possib- 
ilities 
  There is evidence that many of the neurobiological 
changes found in PTSD can be correlated with symptom 
clusters [44]. For example, noradrenergic sensitization may 
be responsible for hyper-arousal symptoms [35] and opioid 
dysfunction may underlie the psychological numbing symp-
toms seen in PTSD. Furthermore, dopaminergic dysfunction 
may mediate symptoms of hyper-vigilance and paranoia 
[34], while Cortisol mediated damage to the hippocampus 
may be responsible for problems with memory and recall. 
Such a schema, though undoubtedly simplistic, may also 
lead to a heuristic approach to the pharmacotherapy and nu-
tritional therapy for PTSD [44]. For example, tricyclic anti-
depressants, which act on the noradrenergic system, may be 
useful in reversing hyper-arousal symptoms. Similarly, 
clonidine, an alpha-2-agonist, which decreases noradrenergic 
output, may also be useful in ameliorating symptoms related 
to sympathetic hyper-arousal. Likewise, medications that 
block dopamine receptors may be useful for patients with 
psychotic or near-psychotic symptoms. Though opioid recep-
tor blockers, such as naltrexone have not been well studied in 
PTSD, they may turn out to have utility. We now know that 
serotonin interacts with a range of other neurotransmitters. 
This may account in part for the promising effects of the 
serotonin re-uptake inhibitors in PTSD. Moreover, evidence 
is emerging which suggest that nutraceutical induced dopa-
minergic activation based on specific gene polymorphisms 
may play an important future role [16]. 
THE NEUROANATOMY OF PTSD 
  On a macroscopic level, recent research suggests that the 
signs and symptoms of PTSD may also have anatomic struc-
tural correlations. For example, we know that sensory input, 
memory formation and stress response mechanisms are   
affected in patients with PTSD. The regions of the brain   
involved in memory processing that have been implicated 
include the hippocampus, amygdala, and frontal cortex. 
Likewise, functional abnormalities within the thalamus,   
hypothalamus, and locus coeruleus may be responsible for 
the heightened stress response (see Table 1).  
  People with PTSD often show structural and functional
 
abnormalities of the brain. The primary regions that have 
been implicated include the limbic  system and prefrontal 
cortex (see Fig. 5) [46].  
  Normally, humans respond to stressful conditions with 
adaptive neurochemical changes that enable us to fight, flee, 
or freeze. These changes are extremely rapid and occur the 
moment our brain recognizes a life-threatening event. The 
areas of the brain that are involved in the control and expres-
sion of mood and emotion, processing and storage of recent 
memories, and in the control of appetite and emotional re-
sponses to food are known collectively as the limbic system.  
Limbic System 
  The limbic system consists of several structures located 
around the thalamus (see Fig. 5) and affects the endocrine 
and autonomic nervous system. It is responsible for our sur-
vival instincts and reflexes, as well as regulating autonomic 
nervous system responses to stress responses and relaxation. 
The structures in the limbic system indicate composite sub-
structures of the forebrain that is variously defined on the 
basis of function and connectivity. These structures are com-
prised of the cingulated gyrus, parahippocampal gyrus, hip-
pocampal formation, septal nuclei, amygdala, hypothalamus, 
epithalamus, as well as the anterior nuclear group of the 
thalamus and portions of the basal ganglia.  
  Three of the structures that are found in the llimbic sys-
tem are of particular importance in PTSD. These are the 
amygdala, hippocampus, and the hypothalamus.  
Amygdala 
  The amygdala receives inputs from the thalamus and the 
cortex, and sends efferents to the brainstem, hypothalamus, 
and striatum. It is likely that these circuits play an important 
role in responding to threatening information via the auto-
nomic, neuroendocrine, and motor systems. Recently, pre-
clinical studies showed that amygdala circuits are involved 
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a rat is shocked each time it hears a particular noise, it devel-
ops a rapid fear-response to that noise (conditioning), con-
trolled through the thalamo-amygdala pathway. If the rat is 
repeatedly exposed to the same noise without being shocked, 
it will gradually lose the fear as behavioral extinction occurs. 
Evidence suggests that this involves the slower cortical-
amygdala pathways, which inhibit the earlier associations. 
Table 1. The Neurochemical Response Patterns to Acute Stress 
Neurochemical  Acute Effects  Brain Regions  Key Functional  
Interactions 
Association with  
Resilience 
Association with 
Psychopathology 
 
Cortisol 
 
Mobilized energy, 
arousal, attention and 
fear.  
Prefrontal cortex, 
hippocampus,  
amygdala  
Increases amygdala & 
Hypothalamus  
corticotropin-releasing 
hormone (CRH).  
Stress-induced increase 
negative feedback  
hypercortisolemia-
depression,  
hypertension,  
Dehydroepian-
drosterone 
(DHEA) 
Has positive mood  
effects 
hypothalamus  Antiglucocorticoid  
actions 
High DHEA-cortisol ratios 
have effects regarding 
PTSD and depression 
Low DHEA cause 
PTSD and depression  
CRH  Fear behaviors,  
increased motor activity,  
reduced reward  
expectations 
Prefrontal cortex, 
cingulate cortex, 
mid brain structures.  
CRH-1 anxiolytic,  
increases cortisol  
and DHEA.  
Reduced CRH release.   increased CRH may 
predispose to PTSD 
and major depression 
Locus coer-
uleus-
norepinephrine 
system 
General alarm function 
increased arousal,  
increased attention,  
fear memory formation.  
Prefrontal cortex, 
amygdala,  
hippocampus,  
hypothalamus 
Activates sympathetic 
axis, inhibits  
parasympathetic,  
stimulates  
hypothalamic CRH 
Reduced responsiveness of 
locus coeruleus-
norepinephrine  
locus coeruleus-
norepinephrine system 
leads to chronic anxi-
ety, hypervigilance.  
Neuropeptide Y  Anxiolytic; counteracts 
CRH and the locus  
coeruleus-
norepinephrine  
Amygdala,  
hippocampus,  
hypothalamus,  
locus coeruleus 
Reduces CRH-related 
actions at amygdala, 
locus coeruleus 
Adaptive increase in 
amygdala neuropeptide Y  
Low neuropeptide Y 
response to stress by 
increased PTSD and 
depression 
Galanin  Anxiolytic; counteracts 
with norepinephrine 
system; impairs fear 
conditioning 
Prefrontal cortex, 
amygdala,  
hippocampus,  
hypothalamus,  
locus coeruleus 
Reduces the  
anxiogenic  
effects of  
norepinephrine  
increase in galanin is  
associated with reduced 
stress, anxiety and  
depression 
low galanin response 
to stress is associated 
with increased PTSD 
and depression 
Dopamine  low nucleus accumbens 
dopamine associated 
with helpless behaviors 
Prefrontal cortex, 
nucleus accumbens, 
amygdala 
Reciprocal interactions 
between cortical and 
sub-cortical dopamine 
systems 
Cortical, subcortical  
dopamine remain  
active to preserve  
reward  
Low dopamine activity 
are associated with 
cognitive dysfunction  
Serotonin  
(5-HT) 
Mixed effects: 5-HT 
stimulation of 5-HT2 
receptors is anxiogenic.  
Prefrontal cortex, 
amygdala,  
hippocampus.  
High levels of cortisol 
decrease in 5-HT1A  
receptors 
High activity of  
postsynaptic 5-HT1A  
receptors cause  
recovery 
Low 5-HT1A receptors 
may predispose 
to anxiety  
and depression 
Benzodiazepine 
receptors 
Acute stress   Prefrontal cortex, 
hippocampus 
decreased 5-HT1A and 
decreased  
benzodiazepine 
receptor function 
Resistance to  
stress-induced  
down-regulation of  
benzodiazepine receptors 
Decreased cortical 
benzodiazepine  
receptors cause panic  
disorder and PTSD 
Testosterone  Stress-induced  
decrease in assertive 
behavior and increase in 
depression 
Hypothalamus  CRH decreases  
testosterone levels 
Increase in testosterone 
activate coping and reduce 
DEP. 
Decreased CSF  
testosterone found  
in PTSD;  
Estrogen  increases in estrogen 
damage (HPA) and NA  
Hypothalamus, 
hippocampus 
increases function of 
benzodiazepine,  
decreases function  
of 5-HT1A receptors 
estrogen may attenuate 
effects of stress-induced 
HPA axis and  
noradrenergic system  
activation 
Long-term increases in 
estrogen down-
regulate 5-HT1A  
receptors  
and increase risk  
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  The amygdala is linked to responses like fear, pleasure, 
feelings of punishment, and awareness of behavior. It re-
ceives input from sensory systems, and it attaches emotional 
meaning to these sensations. It also signals other parts of the 
brain when danger is perceived and sends outputs to the hy-
pothalamus, activating the SNS. In turn, this triggers stress 
catecholamine release, thereby initiating the flight-or-fight 
response. There is evidence that conditions such as PTSD, 
anxiety, autism, depression, narcoleptcy, and schizophrenia 
are linked to amygdala dysfunction secondary to neuro-
transmitter imbalance, structural damage, or developmental 
problems. Several neuroimaging studies have demonstrated 
increased activation of the amygdala in PTSD, though this 
finding is not always consistent [47, 48]. One study demon-
strated an association between a history of neglect and de-
creased amygdala activation [49]. This decreased activation 
may actually serve an adaptive function under certain envi-
ronmental conditions by allowing for continued functioning 
in situations characterized by ongoing threat. However, im-
mobilization defenses such as avoidance, freezing, display of 
submissive behaviors, etc. may occur, and be maladaptive. 
Furthermore, it is not uncommon for persons with an abuse 
history to seek out abusive relationships, part of what psy-
choanalysts refer to as the repetition compulsion, without 
being consciously aware of, or by minimizing the dangers 
involved in such relationships [50].  
Hippocampus 
  Anatomically, the hippocampus resides in the temporal 
lobes, and sends and receives inputs from the amygdala and 
the cortex. This action seems to be mediated in part by corti-
sol through its action on hippocampal glucocorticoid recep-
tors [44]. The hippocampus is the part of the brain that is 
concerned with the formation, organization, and storage of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Legend: Neurobiology, Neurochemical & Physiology of traumatic stress. This figure illustrates some of the key brain structures 
involved in the neurochemical response patterns following acute psychological stress. The functional interactions among the different neuro-
transmitters; neuropeptides, and hormones are emphasized. It is apparent the functional status of brain regions such as the amygdala (neu-
ropeptide Y, galanin, corticotropin-releasing hormone [CRH], cortisol, and norepinephrine), hippocampus (cortisol and norepinephrine), 
locus coeruleus (neuropeptide Y, galanin, and CRH), and prefrontal cortex (dopamine, norepinephrine, galanin, and cortisol) will depend 
upon the balance among multiple inhibitory and excitatory neurochemical inputs. It is also noteworthy that functional effects may vary de-
pending on the brain region. Cortisol increases CRH concentrations in the amygdala and decreases concentrations in the paraventricular nu-
cleus of the hypothalamus. As described in the text, these neurochemical response patterns may relate to resilience and vulnerability and to 
the effects of extreme psychological stress. 344    Current Neuropharmacology, 2010, Vol. 8, No. 4  Bowirrat et al. 
memories. It is believed that the hippocampus is involved in 
the generation and recollection of episodic memories, par-
ticularly memories for personal experiences and facts, and it 
links emotions and sensory inputs (e.g., sights, smells, and 
sounds) in memory. The hippocampus ceases to play a cru-
cial role in the retention of the memory after a period of con-
solidation, such as when we've mastered a new skill. Dam-
age to the hippocampus usually results in profound difficul-
ties in forming new memories, while sparing some aspects of 
memory such as the ability to learn new skills (e.g., playing a 
musical instrument). The hippocampus plays an important 
role in memory, and these circuits may be involved in medi-
ating explicit memories of traumatic events as well as 
learned responses to a constellation of cues ("contextual fear 
conditioning"). Furthermore, preclinical studies demon-
strated that cell death of hippocampal neurons followed by 
hippocampal shrinkage may occur in animals after exposure 
to chronic stressful conditions. This reaction may be medi-
ated in part by hippocampal glucocorticoid receptors [51].  
  Almost a decade ago, research confirmed the involve-
ment of the hippocampus and amygdala in PTSD [47]. More 
recently, positron emission tomography (PET) studies 
showed that veterans with PTSD demonstrated increased 
right amygdala activity when exposed to combat movies 
[52]. Structural magnetic resonance imaging (MRI) studies 
have shown that male combat veterans, women survivors of 
childhood sexual abuse, as well as persons who have been 
diagnosed with major depressive, bipolar and schizophrenic 
disorders, have decreased hippocampal volumes [53]. Given 
the function of the hippocampus, it is not surprising that in 
many of these studies, this change correlated well with 
memory deficits.  
  PTSD involves memories of traumatic events. These dif-
fer from other kinds of memories in several ways. For exam-
ple, traumatic memories may persist over many decades, are 
easily triggered by reminders associated with the traumatic 
events, and their affect-laden quality can make them difficult 
to verbalize. Memory in PTSD patients is also characterized 
by several different kinds of impairments. These include not 
being able to recall specific aspects of the traumatic events. 
Furthermore, these memories can be fragmented and difficult 
to place in chronological context. These clinical symptoms 
are entirely consistent with current evidence of dysfunction 
involving the amygdala and hippocampus, structures that are 
thought to play key roles in the "emotional memory system" 
of the brain [18].  
  Functional neuroimaging of the hippocampus clearly 
demonstrated that it performs a vital role in detection of nov-
elty, episodic memory consolidation and recall, and as a be-
havioral inhibition system. As previously mentioned, there is 
consistent evidence from MRI volumetric studies that hippo-
campal volume is reduced in PTSD. This atrophy of the hip-
pocampus is thought to represent actual decreased neuronal 
density. On the other hand, there are also studies that suggest 
that these structural hippocampal changes may be a part of 
the whole brain and generalized white matter atrophy that 
can often be found in those suffering from PTSD [48]. Sev-
eral reports suggest that stress related glucocorticoids may be 
involved in the atrophy of hippocampal CA3 pyramidal cells. 
The CA3 region of the hippocampus is a major target for 
glucocorticoids in the brain, as it plays an important role in 
regulating the pituitary-adrenocortical response to stressful 
conditions. Glucocorticoid induced atrophy would
 appear to 
require prolonged or repeated bursts of glucocorticoid
  ex-
cess. However, basal glucocorticoid levels have been shown
 
to be lower than normal in PTSD, perhaps due to enhanced 
adrenocortical
  sensitivity to feedback regulation [54]. Fur-
thermore, Yehuda et al., found that dexamethasone admini- 
stration in PTSD enhanced suppression of cortisol [55].  
  The cognitive correlates of the hippocampal damage of-
ten found in PTSD are an impairment of episodic memory 
and novelty detection. This may disrupt executive function, 
resulting in uncertainty, distraction, and anxiety [23]. Press 
et al. reported a 49% reduction of hippocampal volume in 
amnesic patients, with virtually normal parahippocampal 
volumes. These patients showed severe deficits of verbal and 
non-verbal memory, while performing normally on various 
other tasks [23].  
 Since  Bremner  et al., presented evidence that the hippo-
campus of patients suffering from PTSD was reduced in size 
in 1995 [56], many other studies have looked at hippocampal 
volume. Although hippocampal atrophy has not been ob-
served in every single group of patients, it is widely accepted 
that traumatic or prolonged stress can potentially alter the 
size of the hippocampus. Studies using animal models have 
also demonstrated that severe stress can alter hippocampal 
structure and function [53, 57-59].  
  A number of studies have now demonstrated the in-
volvement of
 the hippocampus in chronic PTSD. Two stud-
ies have examined
  the hippocampus without finding volu-
metric changes. The first
 study demonstrated the absence of 
hippocampal atrophy prior
 to the onset of PTSD [60]. Fur-
ther, after single-event
  trauma, hippocampal abnormalities 
did not occur within six months.
 The second study [10] dem-
onstrated smaller
  cerebral volumes and corpus callosum 
measures but no hippocampal
  changes in a group of mal-
treated children.
  
 Sapolsky  [61] has described the sensitivity of hippocam-
pal
 formation to severe, chronic traumatic stress and perhaps 
also
 to elevated glucocorticoids and/or excitatory amino ac-
ids,
  yet many other disorders such as bipolar disorder, 
schizophrenia,
 alcohol misuse and dementia are also associ-
ated with hippocampal
  atrophy [62].  The lateralization of 
hippocampal damage is variable. One
  possible explanation 
for this could be changing vulnerability of the hippocampus
 
to stress-induced damage at different developmental stages.
 
The possibility that small hippocampi represent a predisposi-
tion
 to PTSD was not supported by the one study examining 
acute
 PTSD [60] because no change in volume manifested
 
acutely or within the first six months. Furthermore, Bremner 
et al.  demonstrated no volume difference between early-
onset
  (before age 8 years) and late-onset (age 8 years or 
older)
 abuse [49].
 His group also found an 8% reduction of 
right hippocampal volume in Vietnam veterans with PTSD. 
This change was associated with deficits in verbal short-term 
memory [WMS] [56]. 
 Gurvitis  et al. [63] reported bilateral hippocampal vol-
ume reduction in combat PTSD after controlling for age and 
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greater on the left (26%) than the right (22%), especially 
after controlling for excessive alcohol consumption and 
combat exposure. The decreased hippocampal volume was 
strongly related to combat exposure, PTSD symptom sever-
ity, measures of attention, and memory scores. There were 
no differences in the size of the intra-cranial cavity, whole 
brain, ventricles, ventricle to brain ratio, or the amygdala 
(although, the right amygdala was somewhat larger in PTSD 
patients than in controls).  
 Furthermore,  Bremner  et al. [49] reported a 12% reduc-
tion in the size of the left hippocampus in adult survivors  
of chronic childhood abuse (seven to 15 years of physical/ 
sexual/emotional abuse). Ten percent of this reduction was 
related solely to PTSD after sex, age, education, and alcohol 
abuse were controlled using linear regression. There was also 
a statistically insignificant 5% reduction in right hippocam-
pal size and no differences in caudate or amygdala volume. 
However, there was a larger left temporal lobe in these pa-
tients as compared to controls. The reduced left hippocampal 
volume was not correlated with significant verbal memory 
impairments (immediate and delayed recall and retention), 
trauma onset or duration, years since trauma cessation, or 
PTSD symptom severity.  
  Trauma early in life may damage hippocampal structures, 
but adaptive neuroplastic changes could potentially allocate 
verbal memory processes to other structures, thereby dimin-
ishing the correlation between hippocampal volume and ver-
bal memory impairment. Larger left temporal lobe size could 
account for better visual performance in these patients. This 
may be an adaptation to a loss of verbal capacity. Stein et al. 
[64] also reported a 5% reduction of left hippocampus in 
women survivors of severe childhood sexual abuse. Canive 
et al. [65] reported focal white matter lesions in eight of 42 
combat related PTSD patients using a FLAIR MRI acquisi-
tion. These lesions were located either in periventricular re-
gions or near the white/grey cortical junctions, and were not 
associated with symptom severity or comorbid depression or 
alcohol abuse. The hippocampus may be unique in the brain 
in its ability
 to regenerate neurons [66], with agents such
 as 
phenytoin (anti-epileptic drugs) potentially able to reverse 
stress-activated hippocampal
 atrophy [67]. Moreover, given 
our emergent knowledge on neurogenesis, i.e., the birth of 
new cells in the hippocampus, and the reversibility of corti-
sol-induced neuropathology, there is reason to believe that 
treatment can be effective in helping this condition reverse 
itself [45].  
Hypothalamus 
  Brain function depends on neurochemicals and sub-
stances secreted by the endocrine system. The endocrine 
system uses hormones as chemical messengers. These hor-
mones circulate from one organ to another through the 
bloodstream. The target or destination organ interprets the 
hormonal signals and acts on them accordingly. The endo-
crine and nervous systems are linked by the hypothalamus (a 
centrally located 'switching station' within the brain). The 
hypothalamus is an exceptionally complex region with mul-
tiple components that control many different body functions 
including the regulation of blood pressure, hunger, immune 
responses, body temperature, and maternal behavior. 
  The hypothalamus also is considered to be part of the 
limbic system. It mediates between the nervous system and 
the endocrine system, and helps to regulate blood pressure, 
heart rate, hunger, thirst, sexual arousal, and the sleep/wake 
cycle. The hypothalamus secretes releasing hormones to the 
nearby pituitary in response to nervous system stimuli in-
cluding smell, taste, pain, and emotions. For example, stress-
ful conditions, cold, heat, and other stimuli cause a release of 
CRF from the hypothalamus. The CRF then travels to the 
pituitary. The pituitary is called the "master gland" because it 
produces hormones that regulate a wide variety of bodily 
activities, including growth, blood pressure, pregnancy, sex-
ual function, metabolism, and water balance in the body.  
  Through the HPA axis, the hippocampus and the 
amygdala activate the hypothalamus, which then releases 
CRF. When CRF then activates the pituitary gland, ACTH is 
released. Finally ACTH stimulates the adrenal glands to re-
lease the hormone, cortisol. The level of cortisol is propor-
tional in magnitude to stress level. Using a negative feedback 
loop, it then inhibits the SNS and attenuates the HPA axis. 
The enhanced activity of the SNS and the role of HPA in the 
mechanisms responsible for memory impairment, phobic 
reactions, hyperactivity, obsession, and sleep disturbances 
that are associated with PTSD have been reviewed [17] and 
remain a source of intense investigation.  
Thalamus 
  All sensory information, with the exception of olfaction, 
is communicated through the thalamus to the cerebral cortex. 
Krystal et al. [68] theorized that the thalamus serves as a 
gateway that modulates the access of sensory information to 
the cortex, amygdala, and hippocampus. Lanius and col-
leagues [21] have hypothesized that the thalamus is impor-
tant in the interaction between cognition, affects and behav-
ior. These researchers, along with others, have reported tha-
lamic dysfunction in persons diagnosed with PTSD. This 
dysfunction may disrupt the relay and integration of sensory 
information to the neo-cortex and limbic system. Thalamic 
dysfunction may, therefore, underlie the flashbacks observed 
in PTSD as well as the inability to integrate traumatic memo-
ries into the present.  
  The inability to integrate traumatic memories into the 
present may be related to disruptions in thalamus-mediated 
temporal binding. The latter refers to the 40 Hz oscillations 
in the thalamus, which results in synchronous activity of 
“reentrant thalamocortical loops”. During alert mental activ-
ity, nerve cells in the thalamus oscillate at a frequency of 40 
HZ. The connections of thalamic cells with cells in the cor-
tex have been proposed to lead to similar frequencies of cor-
tical cell oscillations, thus creating reentrant thalamocortical 
feedback loops. Temporal binding has been proposed to be a 
coherent event that binds components of internal and exter-
nal realities into a single construct “the self”. In the absence 
of temporal binding, individuals cannot integrate the totality 
of what is happening to them into personal memory and 
identity. Thus, PTSD has been proposed to be a disorder of 
“thalamocortical dysrhythmia” whereby upper brain struc-
tures would become temporarily disconnected from lower 
structures each time the traumatic memory is accessed, inter-
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Orbitofrontal Cortex 
  The orbitofrontal cortex is a part of the frontal lobes ly-
ing just above the orbit of the eyes. It receives input from 
adjoining cortical and subcortical areas, including the dor-
somedial thalamus, temporal cortex, ventral tegmental area, 
olfactory lobe, and the amygdala. It has efferents to both 
cortical and subcortical regions, including the cingulate cor-
tex, the hippocampus, temporal cortex, lateral hypothalamus, 
and amygdala. The orbitofrontal cortex is uniquely situated 
to facilitate communication between cortical and subcortical 
regions. It is involved in self-regulatory functioning, the   
social engagement and attachment systems, as well as the 
exploratory system. It has been proposed that early abuse, 
within the first two years of life, negatively impacts the 
maturation of the orbital prefronto-limbic system [19].  
Medial Prefrontal Cortex 
  The medial prefrontal cortex has been hypothesized to 
play a role in extinction of conditioned fear responses. By 
exerting control over certain limbic structures, such as the 
amygdala, the medial prefrontal cortex regulates the gener-
alization of fear responses. In PTSD, positron emission to-
mography (PET) studies have shown a negative correlation 
between blood flow in the left prefrontal cortex and the 
amygdala. Additionally, medial prefrontal cortex dysfunction 
has been consistently observed in neuroimaging studies of 
PTSD. It has been hypothesized that this dysfunction is re-
sponsible for attentional and frontal deficits that can resem-
ble dementia. This structure can also suppress the release of 
cortisol, a major stress hormone, through its action on the 
limbic HPA axis. Furthermore, medial prefrontal cortex may 
play a role in the retrieval of episodic memories, and there-
fore could contribute to the timeless nature of traumatic 
memories often observed in patients suffering from PTSD. 
The medial prefrontal cortex also may play a role in self-
referential processing and thus may a play a significant role 
in the set of mindfulness skills that are often utilized to help 
mitigate the affect hyper-arousal often observed in those 
suffering from PTSD [70].  
Anterior Cingulate Cortex 
  Lanius and colleagues [69] noted that the anterior cingu-
late cortex “is a complex structure with multiple functions 
that have been shown to play a key role in the representation 
of subjective experience, integration of bodily responses 
with behavioral demands...and in emotional awareness”. 
Research in mammals has demonstrated that the anterior 
cingulate cortex has extensive connections with multiple 
brain structures, including the amygdala, hypothalamus, nu-
cleus accumbens, ventral tegmental area, substantia nigra, 
raphe nucleus, locus coeruleus, periaqueductal grey area, and 
brainstem autonomic nuclei. Disruptions in the anterior cin-
gulate cortex, as seen in PTSD, may provide a neural basis 
for affect dysregulation, including emotional hyper-arousal 
and numbing. Lanius et al. [69] further pointed out that the 
anterior cingulate cortex “...also plays significant roles in 
other responses crucial to preventing or surviving trauma, 
including pain, response selection, maternal behavior, vo-
calization [the separation cry/call?], and skeletomotor con-
trol”. Psychological trauma, including attachment trauma, in 
the first year of life has been observed to have a negative 
impact on the experience-dependent maturation of the cir-
cuits of the anterior cingulate cortex. 
Insula 
  The insula is a structure located in the cerebral cortex, 
thought to be involved in the emotional response to poten-
tially distressing cognitive stimuli, interoceptive sensory 
stimuli, and somatic sensations. It may serve as an internal 
alarm system through its connection to the amygdala. 
Moreover, Lanius et al. [69] concluded: “As traumatized 
clients learn to slowly increase awareness of body sensa-
tions, movement, and impulses and to tolerate sensation and 
emotional arousal, changes in activation of the insula and 
medial prefrontal cortex may take place, thus increasing their 
ability for self-referential processing of bodily states and 
emotions. Clinically, they have observed that this ability to 
mindfully observe present-moment internal experience, in 
most instances, allows for down-regulation of defensive   
action systems and increased engagement of action systems 
related to daily life, especially the attachment, exploration, 
and sociability systems”. 
Trauma and Lateralization 
  Neuroimaging studies in PTSD suggest that there is in-
creased brain metabolic activity in the right hemisphere dur-
ing recall of traumatic memories, and decreased activity in 
the left hemisphere. PTSD related symptomatology seem to 
be associated with lateral differences, specifically right-
hemispheric dominance. Psychological abuse has been dem-
onstrated to be associated with an increased prevalence of 
left-sided EEG abnormalities and an increased prevalence of 
right-left hemispheric asymmetries [26]. 
  There also seems to be a horizontal disconnect between 
lower and upper brain structures in PTSD as well as evi-
dence demonstrating right-hemisphere dominance during 
traumatic memory recall. However, therapist and patient in 
treatment may have access to an alternative connection be-
tween the hemispheres referred to as the “subcortical 
bridge.” Despite the bifurcation of the hemispheres, this 
bridge remains undivided at lower brain centers. In general, 
it seems that language-based information cannot be ex-
changed readily across this bridge, whereas nonverbal in-
formation crosses more readily. Information indicating dan-
ger or safety can be transmitted across this subcortical 
bridge, leading to adaptive action, including the engagement 
of social support networks in order to ensure psychic and/or 
physical survival. A summary of the neurobiology of PTSD 
is seen in Fig. (3) and Table 2.  
VULNERABILITY AND RESILIENCE 
  Not all individuals who encounter stressful life events 
develop PTSD [71], and there is considerable interest in un-
derstanding what makes an individual vulnerable, and also 
what makes an individual resilient to the deleterious effects 
of traumatic events. Resilience and vulnerability are related 
concepts in a number
  of scientific disciplines but unlike   
resilience, vulnerability
  has not been conceptualized in   
a comprehensive manner. There
  are different disciplinary   
approaches to the concept of vulnerability.
 Vulnerability has Neuro-psychopharmacogenetics and Neurological Antecedents  Current Neuropharmacology, 2010, Vol. 8, No. 4    347 
been defined as the potential for loss [72] or the potential for 
casualty when exposed to a hazard or threat. The Interna-
tional Strategy for Disaster Reduction (2004) defines
 vulner-
ability as the predisposition of individuals or societies
 to be 
affected by disaster the inability to manage disaster [73]. 
They also divide vulnerability into external and internal fac-
tors. The
 external factors relate to external shocks and envi-
ronmental
  stresses, whereas the internal factors are associ-
ated with inability
 to cope with trauma. Vulnerability is diffi-
cult to quantify
 but it may be increased or decreased depend-
ing on the actions taken in response to the trauma [74].  
  There is a plethora of research surrounding this issue 
focused on identifying mediating factors that are associated 
with increased (vulnerability) or decreased (resilience) risk 
for developing PTSD following traumatic stress [74] (see 
Table 1). Many variables seem to be associated with the risk 
of developing PTSD. These include the nature of the precipi-
tating event, genetic vulnerability, history of previous 
trauma, preexisting psychiatric disorder, family history of 
psychiatric disorder, insufficient support systems. The char-
acteristics of the event (e.g., direct physical harm, proximity 
to threat, pattern duration and severity of the trauma), the 
characteristics of the traumatized individual, nature of the 
recovery environment, and the characteristics of fam-
ily/social system (e.g., supportive, calm, nurturing vs. cha-
otic, distant, absent, anxious) all impact the risk of develop-
ment of PTSD. Social support particularly via close mean-
ingful relationships seems to be exceptionally important and 
it appears that positive social support of high quality can 
enhance resilience to stress, help protect against developing 
trauma-related psychopathology, decrease the functional 
consequences of trauma-induced disorders such as PTSD, 
and even reduce medical morbidity and mortality [75].  
  Despite strong evidence demonstrating the beneficial 
effects of family and social support on medical and psycho-
logical wellbeing, the field of psychiatry has contributed 
relatively little to developing, testing, and implementing ef-
fective evidence-based interventions aimed at increasing 
social support for patients and at-risk populations. Thus, im-
pairments in personal adjustment, lack of supportive rela-
tionships, family history of PTSD, previous traumatic expe-
riences and other existing mental disorders all play a role in 
vulnerability to developing PTSD.  
Table 2. Summary of Neurobiology of PTSD 
•  Abnormalities in Sympathetic branch 
Severe stress causes dysfunction of locus coeruleus causing hypersensitivity to external stimuli 
•  Studies of combat veterans vs. non-combat veterans 
Differences in combat veterans:  
-  Increased heart rate and anxiety during combat related stimuli 
-  Increased urinary excretion of NE in PTSD patients 
-  Abnormalities of the Hypothalamic Pituitary Adrenal Axis (HPA) 
-  In acute /chronic stress and major depression: Cortisol levels increase 
•  Among non-combat veterans                           No change 
•  In PTSD, sensitization of the HPA occurs: 
-  Cortisol levels are chronically decreased 
-  Patients with PTSD show lower cortisol levels up to 50 years post trauma 
-  Lower cortisol levels immediately after trauma, risk factor for development of PTSD later date 
•  Hipocampal MRI measurements smaller in PTSD 
-  Correlates with severity of trauma 
-  Cognitive deficits 
-  PTSD symptoms 
•  Functional neuro-imaging whilst traumatic material is shown 
-  Hyperactive amygdale 
-  Anterior paralimbic regions activated 
-  Decreased activity in anterior cingulate cortex 
-  Decreased blood flow to hippocampus 
•  Summary Model of PTSD 
-  Amygdala and related structures are overactive 
-  Also known as “hot and emotional” memory system 
-  Hippocampus and anterior cingulated cortex is underactive  
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Genetic Predisposition to PTSD: Vulnerability Risk 
  Based on twin studies it has been posited that genetic 
factors can influence the risk of developing PTSD. As in 
combat veterans, the development of PTSD symptoms after 
non-combat trauma also seems to be moderately heritable. 
Moreover, many of the same genes that influence exposure 
to assaultive trauma appear to influence susceptibility to 
PTSD symptoms in their wake. 
  The dopamine and opioid reward pathways of the brain 
are critical for survival by providing for the pleasure drives 
for eating, love and reproduction. These are called 'natural 
rewards' and involve the release of dopamine in the nucleus 
accumbens and frontal lobes. However, the same release of 
dopamine and production of sensations of pleasure can be 
produced by 'unnatural rewards' such as alcohol, cocaine, 
methamphetamine, heroin, nicotine, marijuana, and even 
compulsive behaviors such as gambling, eating, sex, and risk 
taking. Since only a minority of individuals become addicted 
to these compounds or behaviors, it is reasonable to ask what 
factors distinguish those who do become addicted from those 
who do not. It is no longer believed that the continuation of 
the destructive behaviors is entirely voluntary or that envi-
ronmental factors play the major role. Since all of these be-
haviors have a significant genetic component, the presence 
of one or more variant genes presumably acts as a risk factor 
for these behaviors. Since the primary neurotransmitter of 
the reward pathway is dopamine, genes for dopamine syn-
thesis, degradation, receptors, and transporters are reasonable 
candidates. Moreover, neurons containing receptors for sero-
tonin, norepinephrine, GABA, opioid, and cannabinoid all 
seem to modify dopamine metabolism and dopamine neu-
rons as well as drug treatment response. 
 Blum  et al. [76] and Comings and Blum [77] have pro-
posed that defects in various combinations of the genes for 
these neurotransmitters result in a Reward Deficiency Syn-
drome [76,78] and that such individuals are at risk due to 
behaviors used in seeking unnatural rewards. Because of its 
importance, the gene for the dopamine D2 receptor was a 
major candidate gene. Studies in the past decade have shown 
that in various subject groups the Taq I A1 allele of the 
DRD2 gene is associated with alcoholism, drug abuse, smok-
ing, obesity, compulsive gambling, and several personality 
traits. One major area of importance is the potential for gene 
involvement in vulnerability to PTSD. A range of other do-
pamine, opioid, cannabinoid, norepinephrine, and related 
genes has since been added to the list. Like other behavioral 
disorders, these are polygenically inherited and each gene 
accounts for only a small per cent of the variance [77].  
  The first study on genes associated with vulnerability and 
PTSD came from the laboratory of Comings et al. [79]. In 
their study, subjects on an addiction treatment unit who had 
been exposed to severe combat conditions in Vietnam were 
screened for PTSD. Of 24 with PTSD, 58.3% carried the 
D2A1 allele. Of the remaining eight who did not meet PTSD 
criteria, 12.5% carried the D2A1 allele (p = 0.04). In a repli-
cation study of 13 with PTSD, 61.5% carried the D2A1 al-
lele. Of the remaining 11 who did not meet criteria for 
PTSD, 0% carried the D2A1 allele (p = 0.002). For the com-
bined group 59.5% of those with PTSD carried the D2A1 
allele versus 5.3% of those who did not have PTSD (p = 
0.0001). These results suggest that a DRD2 variant in link-
age disequilibrium with the D2A1 allele confers an increased 
risk for PTSD, and the absence of the variant confers a rela-
tive resistance to PTSD. Along similar lines others have con-
firmed that the DRD2 A1 allele was associated with PTSD. 
However, this association was found only in the harmful 
drinkers. PTSD patients with the A1 (+) allele consumed 
more alcohol than patients with the A1 (-) allele. The impor-
tance of determining alcohol consumption in DRD2 associa-
tion studies with PTSD is suggested [80]. These results sug-
gest that negative association with the DRD2 A1 allele in 
PTSD may be due experimental flaws [81]. Further confir-
mation has revealed that the DRD2 A1 allele was responsible 
in part for an enhanced increase in social functioning follow-
ing anti-depressant therapy compared to the DRD2 A2 allele 
[82]. More recently it was found that the 957C>T polymor-
phism in the DRD2 gene is one of the genetic factors for 
susceptibility to PTSD [37]. 
  Other dopaminergic genes may also contribute to PTSD 
vulnerability. Specifically, Segman et al. [83] evaluated 102 
chronic PTSD patients and 104 carefully-documented trauma 
survivors who did not develop PTSD. Significant excess of 
nine repeat allele was observed among PTSD patients (43% 
vs. 30.5% in trauma survivor controls; chi(2) = 6.3, df = 1, p 
= 0.012). An excess of nine repeat homozygous genotype 
was also observed in PTSD (20.43% in PTSD vs. 9.47% in 
trauma survivor controls; chi(2) = 6.11, df = 2, p < 0.05). 
These findings suggest that genetically determined changes 
in dopaminergic reactivity may contribute to the occurrence 
of PTSD among trauma survivors. Others have also associ-
ated MAO-B activity, and genotyping of this gene might be 
used as a peripheral marker of the psychotic symptoms in 
PTSD [84].  
  In terms of vulnerability genes associated with PTSD risk 
Mustapic et al. [85] evaluated DBH-1021C/T gene polymor-
phism in combat veterans and found with (N = 133) or with-
out (N = 34) in veterans with chronic PTSD. Similar fre-
quencies in genotype or allele distribution were found be-
tween veterans with or without PTSD. War veterans with 
PTSD had lower dopamine beta hydroxinase (DBH) activity, 
associated with the DBH-1021C/T variant in DBH genes, 
than veterans without PTSD. A significantly lower plasma 
DBH activity was found in combat veterans with PTSD car-
rying the CC genotype as compared to veterans without 
PTSD carrying the corresponding genotype. Since both 
groups were exposed to the same trauma, it is possible that a 
preexisting trait difference in regulation of nor-epinephrine 
function contributed to a differential vulnerability to develop 
PTSD, or that the regulation of DBH expression was differ-
ent in response to trauma. The results suggest that that geno-
type-controlled measurement of plasma DBH activity might 
be used as a potential biological marker of the response to 
trauma, and that further studies of DBH and other loci re-
lated to dopamine and nor-adrenolin in PTSD are warranted. 
 Lee  et al. [86] examined the possible association between 
the serotonin-transporter-linked polymorphic region (SERTPR) 
and PTSD. The genotype and allele frequencies of the 
SERTPR were analyzed in 100 PTSD patients and 197   
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frequency of the s/s genotype was significantly higher in 
PTSD patients than in normal controls. These findings suggest 
that the SERTPR s/s genotype is one of the genetic factors for 
the susceptibility to PTSD. 
  Moreover, acute stress, which can also induce PTSD in  
at risk individuals, has been found to alter the expression   
of cholinergic genes. In fact results suggest a model in   
which robust cholinergic stimulation triggers rapid induction 
of the gene encoding the transcription factor c-Fos. This   
protein then mediates selective regulatory effects on the 
long-lasting activities of genes involved in acetylcholine 
metabolism [7]. 
  GABA systems have been implicated in the pathogenesis 
of anxiety, depression and insomnia. These symptoms are 
part of the core and comorbid psychiatric disturbances in 
PTSD. In a sample of Caucasian male PTSD patients, 
dinucleotide repeat polymorphisms of the GABA(A) recep-
tor beta 3 subunit gene were compared to scores on the Gen-
eral Health Questionnaire-28. A study by Freusner et al. [87] 
indicates that in a population of PTSD patients, heterozygos-
ity of the GABRB3 major (G1) allele confers higher levels 
of somatic symptoms, anxiety/insomnia, social dysfunction 
and depression than found in homozygosity.  
  Additionally, previous studies have reported associations 
between apolipoprotein E (APOE) genotype, cognitive func-
tion, and psychopathology in psychiatric populations. Free-
man et al. [88] investigated the associations between APOE 
allele status, memory function, and symptom severity in 
PTSD subjects. The presence of the APOE 2 allele was asso-
ciated with significantly worse re-experiencing symptoms 
and impaired memory function in this population. Further-
more, studies have also shown that a putative association of 
the cannabinoid receptor (CNR)1 gene may be a risk factor 
for attention deficit hyperactivity disorder (ADHD), and pos-
sibly PTSD [89].  
  In terms of prolonged memory of traumatic experiences, 
recent studies in mice have been suggestive that Myo6   
gene may be selectively and rapidly up-regulated to play a 
hitherto unidentified role in the maintenance of the integrity 
and functionality of the hippocampus after traumatic stress 
[90].  
  Using microarray assays others have associated PTSD 
with decreased activity in the dorsolateral prefrontal cortex, 
the brain region that regulates working memory and prepara-
tion and selection of fear responses. Su et al. [91] investi-
gated gene expression profiles in dorsolateral prefrontal cor-
tex (Brodmann’s area 46) of postmortem patients with (n=6) 
and without PTSD (n=6) using human mitochondria-focused 
cDNA microarrays. Their study revealed PTSD-specific ex-
pression fingerprints of 800 informative mitochondria-
focused genes across all of these 12 samples from Brod-
mann’s area 46, and 119 (+/->1.25, p<0.05) and 42 (+/-
>1.60, p<0.05) dysregulated genes between the PTSD and 
control samples. Quantitative RT-PCR validated the microar-
ray results. These fingerprints can essentially distinguish the 
PTSD dorsolateral prefrontal cortex from controls. Of the 
119 dysregulated genes (+/-> or =125%, p<0.05), the highest 
percentages were associated with mitochondrial dysfunction 
(4.8%, p=6.61 x 10(-6)), oxidative phosphorylation (3.8%, 
p=9.04 x 10(-4)), cell survival-apoptosis (25.2%, p<0.05) 
and neurological diseases (23.5%, p<0.05). Fifty dysregu-
lated genes were present in the molecular networks that are 
known to be involved in neuronal function-survival and con-
tain seven targets for neuropsychiatric drugs. Thirty of the 
dysregulated genes are associated with a number of neuro-
psychiatric disorders. Their results indicate mitochondrial 
dysfunction in the PTSD dorsolateral prefrontal cortex, and 
provide the expression fingerprints that may ultimately serve 
as biomarkers for PTSD diagnosis and the drugs and molecu-
lar targets that may prove useful for development of reme-
dies for prevention and treatment of PTSD. 
  Moreover, it has been found that several single nucleo-
tide polymorphisms (SNPs) in FK506 binding protein 5 
(FKBP5) interact with childhood trauma to predict severity 
of adult PTSD [92]. These findings suggest that individuals 
with these SNPs who are abused as children are more sus-
ceptible to PTSD as adults. This is particularly interesting 
given that FKBP5 SNPs have previously been associated 
with peritraumatic dissociation (that is, dissociation at the 
time of the trauma) [93] which has itself been shown to be 
predictive of PTSD [6, 94]. Furthermore, FKBP5 may be 
less expressed in those with current PTSD [93-95]. There is a 
new finding in which two neurotransmitters are reduced after 
traumatic brain injury: hypocretin (orexin) and melanin con-
centrating hormone neurons (MCH) in the hypothalamus 
[96].  
  In summary, a number of genes have been associated 
with PTSD. These include serotonergic, dopamineergic 
(DRD2, DAT, DBH), glucocorticoid, GABA (GABRB), and 
apolipoprotein systems (APOE2), brain-derived neurotrophic 
factor, Monamine B activity, CNR1, Myo6, CRF-1 and 
CRF-2 receptors, neuropeptide Y (NPY), orexin and MCH. 
However, the complex etiology of PTSD, for which experi-
encing a traumatic event forms a necessary condition, makes 
it difficult to identify specific genes that substantially con-
tribute to the disorder. Gene-finding strategies are difficult to 
apply. Interactions between different genes and between 
them and the environment probably make certain people 
vulnerable to developing PTSD [28, 92, 94-96]. More gene-
environmental studies are needed that focus more narrowly 
on specific, distinct endophenotypes and on influences from 
environmental factors. 
Resilience 
  Masten [97] refers to resilience as a pattern of positive 
adaptation in the context of significant risk or adversity. It is 
the process to “bouncing back” from difficult experiences. 
Janoff and Bulman [98] also described traumatic events as 
rebuilding shattered assumptions; traumatic life events shat-
ter our fundamental assumptions about our world and our-
selves: the benevolence of the world; the worthiness of the 
self; and the world as meaningful. In the aftermath of these 
extreme experiences, coping involves the task of reconstruct-
ing an integrated assumptive world that incorporates the 
traumatic experience. Resilience is different from recovery 
in that it represents a distinct and empirically separable out-
come trajectory from that normally associated with recovery 
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  Bonanno [74] has defined resilience as the
  ability to 
maintain a state of normal equilibrium in the face
  of ex-
tremely unfavorable circumstances. To enhance resilience,
 it 
is necessary to have an understanding of its determinants.
 
Various factors such as beliefs, attitudes, coping strategies,
 
behaviors and psychosocial cohesion have been suggested as
 
conveying protection or endorsing resilience in the face of
 
trauma. Other factors, such as religious faith and socio-
political effectiveness, have been argued to produce resil-
ience because they induce a sense of self control. Each medi-
ating factor can be related to the degree to which they either 
prolong or attenuate and individual’s stress-response activa-
tion resulting from the traumatic experience [98]. Resilient 
individuals may show insight, have initiative,
 use humor and 
be creative and independent. It is a dynamic quality and there 
may be discontinuities in resilience as people, situations,
 
opportunities, and environment change.
  
  Psychological resilience is seen as a relatively stable per-
sonality trait characterized by the ability to bounce back 
from negative traumatic events and to return to a state of 
harmony and balance. Flexible adaptation to the ever-
changing demands of life builds resilience. Resilient people 
are optimistic, they maintain hope about future outcomes. 
Such optimism is associated with the use of active, problem-
focused coping when dealing with stressful life events [100].  
  In fact many resilient people have optimism, even in dire 
situations. While in some people optimism appears to be 
genetic, it can also be learned. For example, cognitive-
behavioral therapy in part is designed to enable people to 
view their situation in a more positive light and to see ways 
out of a difficult situation [101]. Having a moral compass or 
a set of beliefs that few things can shatter can get a person 
through very tough times. Indeed, faith or spirituality has 
some overlap with a moral compass, and for some people 
can provide comfort and a sense of optimism and hopeful-
ness in the face of traumatic situations [100].  
  Resilient people are self-efficient; they believe that they 
have the skills necessary to effectively cope, manage or 
withstand hardship and to accomplish any difficult task. 
Lack of predictability and control are the central issues for 
the development and maintenance of PTSD. Resilient people 
have a sense of mastery,  they believe that they can exert 
positive control over the environment. They believe that by 
breaking down complex problems into smaller, more man-
ageable tasks and goals, they can achieve a series of immedi-
ate successes [101]. These successes enhance their feeling of 
mastery and control over the problem [101]. Another charac-
teristic that resilient people have is cognitive flexibility, 
which enables the person to see the experience as an oppor-
tunity for personal growth. Meaning that the experience of 
severe trauma can be used to discover and develop new skills 
and strengths, and gain insights. What is especially interest-
ing about this is that it seems to imply that PTSD is not 
caused only by the negative events themselves, but by how 
individuals interpret those events [102]. 
  Recently Pitman’s group concluded from a series of ex-
periments that found combat veterans with PTSD have func-
tional abnormalities in the anterior cingulate cortex, 
amygdala, and hippocampus. They most recently found, en-
hanced resting metabolic activity in the dorsal anterior   
cingulate cortex/midcingulate cortex (dACC/MCC). This 
appears to represent a familial risk factor for developing 
PTSD after exposure to psychological trauma [103]. More- 
over, a clinical characteristic of PTSD is persistently   
elevated fear responses to stimuli associated with the   
traumatic event. Milad et al. [22] found that fear extinction is 
impaired in PTSD. They further suggest that dysfunctional 
activation in brain structures that mediate fear extinction 
learning, and especially its recall, underlie this impairment  
in combat veterans.  
  The question of whether or not there is a genetic or an 
inborn acquired biological marker for PTSD is best exempli-
fied by the recent work of Metzger [104]. These investiga-
tors explored an identical-twin, case-control design to inves-
tigate whether these abnormalities reflect pre-trauma vulner-
ability or the acquired consequence of PTSD. Vietnam com-
bat veterans and their non-combat-exposed, identical twins 
completed a three-tone oddball task. It was found that Veter-
ans with PTSD had delayed target N2 latencies compared to 
veterans without PTSD. In a small non-medicated, nonsmok-
ing subsample, veterans with PTSD also had significantly 
diminished target P3b amplitudes. A mixed-model, random-
effects analysis on the non-medicated, nonsmoking subsam-
ple that included the combat-unexposed co-twins showed   
a significant Diagnosis x Combat Exposure interaction   
for target P3b amplitude. Results replicate increased N2   
latency and diminished P3b amplitude in PTSD and suggest  
that diminished P3b amplitude is an acquired condition in 
PTSD. 
  Through the era of protinomics we are finding gene ex-
pressions that are impacted by our environment, and stress is 
a powerful environmental pressure that, because of gene 
polymorphisms, predicts clinical outcomes in terms of pes-
simism and optimism. This fact leads us to believe that ge-
netic diagnosis and genome targeting of treatment of PTSD 
will ultimately result in a more personalized approach to this 
complex devastating disorder. Based on the available litera-
ture and studies it seems prudent that soldiers should be sub-
ject to genetic, neuroimaging and psychometric testing prior 
to combat. This screening for vulnerability to PTSD could 
reduce the enormous burden placed on society, the govern-
ment and the famlies of its victims.  
CLINICAL ISSUES: FROM BENCH TO BEDSIDE 
  A considerable amount of research has found that trauma 
has negative impacts on different body systems, impacting 
physical, psychological, and behavioral health. In other 
words, trauma may lead to poor health outcomes. Research 
also shows that these neurochemical changes may relate to 
abnormalities in thyroid and other hormone functions, and to 
increased susceptibility to infections and immunologic dis-
orders associated with PTSD. The psychological and behav-
ioral effects of PTSD on health may be accounted for in part 
by comorbid depressive and anxiety disorders. There is some 
evidence that neurochemical changes in PTSD are related to 
cardiovascular, gastrointestinal, and musculoskeletal disor-
ders. These studies found that self-report of circulatory dis-
orders and symptoms of cardiovascular trouble were associ-
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women, and male firefighters [6, 20, 105, 106,]. Among 
studies that have examined PTSD in relation to cardiovascu-
lar illness via  physician diagnosis or laboratory findings, 
PTSD has been consistently associated with a greater likeli-
hood of cardiovascular morbidity. In a recent study, re-
searchers used electrocardiogram (ECG) findings to compare 
the cardiovascular function of Vietnam veterans with PTSD 
to the cardiovascular function of veterans without PTSD. 
After controlling for risk factors such as alcohol consump-
tion, weight, current substance abuse, and smoking, in addi-
tion to controlling for current medication use, PTSD was 
found to be associated with nonspecific electrocardiogram 
abnormalities, atrioventricular conduction defects, and in-
farctions. Because the PTSD group in this study included 
only those veterans with severe PTSD, it is important to in-
terpret this study with caution. It is unknown whether men 
with less severe PTSD would show the same electrocardio-
gram abnormalities [20]. There have been only a small num-
ber of studies specifically addressing cardiovascular abnor-
malities in women [6]. Gastrointestinal and musculoskeletal 
systems dysfunctions have also been shown to be associated 
with PTSD, but the relationship of PTSD to these two sys-
tems has not been as extensively researched as the relation-
ship between PTSD and the cardiovascular system [105]. 
The majority of the studies that have been conducted have 
gathered information about veterans, but a study of civilian 
young men and women found that there is a relationship be-
tween gastrointestinal symptoms and PTSD. Similarly, re-
searchers found that PTSD was related to musculoskeletal 
symptoms among male firefighters [106]. Additional re-
search is needed to learn more about how these and other 
bodily system troubles may be related to PTSD.  
Case Reports  
  The following three case reports from the Department of 
Psychiatry, University of Florida, College of Medicine, 
Gainesville, Florida reflect the unfortunate circumstances 
that many patients with PTSD must deal with and potentially 
resolve. 
Rape Victim  
  Maureen is a 24 year old obese female who presented to 
our facility after a 9 day drug detoxification followed by 1 
month of primary drug rehabilitation. She was referred to our 
facility due to concern that she was a victim of sexual abuse 
and suffered from co-exisisting PTSD. It was felt that this 
was hindering her from maintaining sustained recovery from 
polysubstance addiction with a preference for IV opioids: 
alprazolam, and crack cocaine. She had been in multiple 
rehabilitation facilities since the age of 15 and had been un-
able to achieve abstinence longer than two months. We were 
advised that she was a “runner”, having absconded from the 
referring facility only to return intoxicated, bruised, beaten 
and raped. There were also reports of her wandering off 
while on campus, and being found “spaced out “with no rec-
ollection of how she ended up at her destination”. She also 
had a history of self mutilation (cutting), one intentional drug 
overdose, running away from home and living on the streets 
as well as prostitution. She had also a history of violent short 
term unstable relationships. The referring facility sent her 
with the diagnosis of PTSD, depression, dissociative disor-
der, polysubstance dependence and borderline personality 
disorder. 
  Maureen was a single child from a well to do family. She 
reports sketchy “dream like” memories of her father abusing 
and raping her over a 10 year period between the ages of 6 
and 16 when she ran away from home. Her father, a minister 
claimed she was making this up and that she was violent and 
unstable. He was willing to pay for her treatment. Her 
mother also denied that there was any validity to these 
claims. There was never any objective evidence found that 
corroborated these claims. Though her father willingly paid 
for her treatment, he remained distant, unavailable for phone 
conferences and unwilling to participate in any family ses-
sions. He did not visit her nor call during her nine month 
stay. 
  Upon arrival she underwent psychiatric evaluation. 
Medications upon arrival included escitalopram and PRN 
quetiapine for anxiety. After evaluation, quetiapine was dis-
continued due to her problem with weight control as well as 
the perception that she was abusing it for its sedative effect. 
Ziprasidone was added and titrated up to 80 mg bid, and pra-
zosin QHS was prescribed for violent dreams. It was noted 
that she appeared sedated upon arrival. A urine drug screen 
was done which was positive for benzodiazipines. When 
confronted, she initially denied this, but a thorough search of 
her belongings revealed 1mg clonazepam tablets concealed 
in her alarm clock. She admitted to taking clonazepam dur-
ing the entirety of her stay at the primary facility, and it was 
confirmed that their UDS would not pick up this particular 
benzodiazepine. She underwent a clonazepam taper at our 
facility without any problems. 
  During a three week primary phase she was introduced to 
relaxation and self soothing exercises, and developed a trust-
ing relationship with her therapist. She then began the sec-
ond phase of treatment. While constructing a time line of her 
life, there were significant problems with remembering time 
periods and events. Her roommates were suspicious that she 
had resumed cutting herself. Examination of her medial up-
per arm revealed numerous lacerations and a search of her 
cabin revealed razor blades. She explained that she had been 
cutting on and off for many years, had stopped it for awhile 
but resumed it when she began doing her assignments be-
cause it “made her feel calm”. Her treatment stay was also 
complicated by frequent visits to the medical unit for head-
aches and stomach aches. This intensified with phase 2 of 
treatment. There were also intense outbursts when the medi-
cal staff refused to grant her sick passes or change her medi-
cation to include daytime doses of quetiapine. There were 
also dissociative episodes where she would wander off dur-
ing group without any recollection of doing so. She was 
placed back in phase 1 for several weeks then successfully 
transitioned to phase two. She complained of a constant state 
of anxiety and feelings that her father was spying on her. She 
also began suffering violent dreams and bouts of screaming 
and crying during groups when relating her experiences. Her 
memories were vivid during these episodes, claiming that 
she could feel his presence and smell his aftershave. She also 
had severe drug cravings and was found attempting to sneak 
away while attending off campus Narcotics Anonymous 
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  Progress was slow as it was felt that a gradual and deli-
cate approach to exposure therapy was needed to avoid re-
traumatization. Finally, after many months she was able to 
complete her timeline and write a letter to her abuser though 
she refused to mail it. She also began to embrace NA, ob-
tained a sponsor, and began working the 12 steps. Though 
her anxiety remained at a fairly high level, her depression 
improved and her dissociative episodes decreased. Finally, 
after nine months she entered a half way house and began to 
do volunteer work at a rape support group. She continues to 
participate in outpatient therapy. She still has occasional 
flashbacks, though has been unable to identify triggers. She 
feels very uneasy in the proximity of churches stating that 
the remind her of her father. She is also unwilling to attend 
any AA or NA meetings that are held in churches for the 
same reason. She is continuing to work with a therapist on 
these issues.  
Death Threat Victim 
  Doug is a 44 year old male who presented to our pain 
medicine clinic with multiple pain complaints including 
groin, abdominal, knee, back, chronic headaches and “all 
over” pain for which he carried the diagnosis of fibromyal-
gia. This was his second appointment as he had missed his 
first due to “transportation problems”. During the history, he 
seemed very anxious and hyper-alert. It was also noted that 
he had moved the chair to the far wall facing the door. Doug 
had multiple complaints of difficulty sleeping, irritable 
bowel syndrome, anxiety and various pain disorders. He had 
a right rotator cuff injury and multiple urological evaluations 
for testicular pain where no etiology was found. He had had 
a non-chaotic childhood. He was an only child with an over 
attentive mother. He had attended college and had worked 
for a well known industrial corporation receiving a fairly 
good salary until four years ago. Currently he is unemployed 
and living alone off of savings and a small stipend provided 
by his parents. He had no car. 
  There were some inconsistencies during his history re-
lated to the onset of the various pain complaints, but he kept 
alluding to a “work injury” approximately four years ago, 
though he would not initially provide specifics. Up until ap-
proximately an hour into the interview, he was being evasive 
in providing anything specific. Doug then became tearful. 
After some reassurance and coaxing he explained that his 
problems began at work approximately four or five years 
ago. He also denied ever sharing this with anybody else due 
to fear and shame. He reported being very meek by nature 
and had been picked on all of his life. While at work a su-
pervisor tormented him relentlessly and ridiculed him in 
front of his peers. Over time the supervisor became increas-
ingly abusive with “accidental” pushing and shoving as well 
as grabbing is genital area as well as threats of perverse sex-
ual molestation. He was also told that if he told anyone or 
complained, that the supervisor, who frequently bragged 
about his violent history as well as his gun and knife collec-
tion would “hunt him down and kill him”. 
  As this continued over many months, Doug began to call 
in sick frequently to work. He began having difficulty sleep-
ing and bouts of diarrhea. He finally “summed up his cour-
age” and went to one of the managers and complained that 
he was being verbally abused by his supervisor and asked to 
be relocated. The supervisor was interviewed, denied any 
abuse and agreed to be a less forceful boss with Doug. A 
meeting was set up between the three where the supervisor 
apologized to Doug. Things got better at work with both 
Doug and the supervisor avoiding each other. Several weeks 
later, the supervisor came up behind Doug grabbed his testi-
cles and began squeezing saying that he was indeed going to 
kill him. According to Doug, he briefly passed out from the 
pain. He then left work, noted that his testicles were bruised 
and swollen, went to the emergency room and related falling 
while straddling a bicycle, injuring himself. He was given 
pain pills and set up with urology, though did not follow 
through with the appointment. He went back to the manager, 
stated he had been “grabbed “by his supervisor, again re-
questing relocation. The manager said he would have a talk 
with the supervisor and would think about the transfer. After 
a few days, the supervisor brushed by him and said “I am 
going to kill you”. Doug never went back to work. He moved 
to a different state and found a small apartment. 
  Since that time he has become increasingly reclusive. He 
denies having any friends or social life. He rarely leaves his 
apartment. He sold his car to a brother and now walks about 
everywhere. He has purchased several guns. He keeps one 
his pillow at night, and the others scattered throughout his 
apartment. He claimed to have one in his backpack. He be-
lieves his ex-supervisor is stalking him. He has heard that the 
supervisor left his job a couple of months after Doug did. He 
cannot sleep at night, has violent dreams where he is ab-
ducted, tortured and killed by his ex-supervisor or his 
friends. He is hyper alert and “jumps at the slightest noise”. 
He admitted missing his first appointment because he was so 
fearful of public transportation. 
  He was placed on an SSRI, NSAIDS, received knee in-
jections which have been helpful. He is being evaluated by 
urology for testicular pain, though no etiology has yet been 
found. He was referred to psychiatry for depression and psy-
chotropic medical management. He is also being seen by a 
psychologist where he is receiving outpatient counseling for 
PTSD. He has purchased a used car, and is looking into dis-
ability. He has also shared his story with his brother and oth-
ers and has sought out the services of an attorney who is pre-
paring a case against the corporation. His many somatic 
complaints are slowly improving.  
Iraq Veteran 
  Jim is a 32 year old veteran of the war in Iraq who pre-
sented to our facility with the diagnosis of PTSD, depression 
and alcoholism. While in Iraq, he and a close friend encoun-
tered an improvised explosive device while driving together. 
The explosion resulted in the driver sustaining critical cra-
niofacial injuries while Jim sustained a broken femur. Jim 
was trapped in the passenger seat and was able to hold his 
injured friend’s airway open until the medics arrived. Unfor-
tunately, his friend, though initially conscious and lucid, died 
as they were being extricated from the damaged vehicle. Jim 
underwent successful emergency ORIF (Open Reduction 
Internal Fixation) of his femur, which was broken in the ex-
plosion and recovered full use. Jim returned to the states and 
was given a hero’s welcome by his home town. According to Neuro-psychopharmacogenetics and Neurological Antecedents  Current Neuropharmacology, 2010, Vol. 8, No. 4    353 
his wife, he was uncharacteristically quiet during the drive 
home. He became increasingly withdrawn and experienced 
crying spells. Though previously known for his ability to 
solve problems and multitask, he was overwhelmed by even 
the smallest problems. His mood was labile, his temper short 
and he smoked heavily. Two weeks later, he and his wife had 
a small disagreement and he slapped her, and immediately 
apologized and began to cry. He would toss and turn in his 
sleep, crying out at times. His dreams were vivid, and vio-
lent, and frequently the theme was observing one of his 
friends or a family member in a perilous situation while he 
was physically paralyzed, unable to speak or move and 
forced to helplessly watch them die. Though always a heavy 
drinker and a gregarious outgoing entertainer, he now 
avoided his friends and began drinking even more heavily, 
while alone. He would drink to intoxication every night and 
incurred a DUI when he was noted to be swerving. His 3 
year old daughter was in the car at the time. He was always 
on edge and would startle when the phone or doorbell rang. 
He was extremely lethargic during the day, his speech and 
movement increasingly slow. He admitted to feeling guilty 
about surviving the explosion, and would have episodes that 
resembled panic attacks where he believed that he was back 
in the destroyed car with his dying friend and would begin 
screaming for help. He also avoided watching the news and 
refused to talk about Iraq. He would frequently drive around 
town alone at night, drinking alcohol and talking to himself. 
After his second DUI, he was sent to our rehabilitation facil-
ity that specialized in alcoholism, drug addiction and PTSD. 
While in treatment, Jim was introduced to 12 step recovery, 
which he embraced, obtaining a sponsor who was also a vet-
eran that had sustained war injuries. He was in treatment for 
three months where he learned techniques to deal with anxi-
ety and obtained treatment for depression. He attended coun-
seling groups with other veterans, and over time became 
increasingly able to share his experiences without reliving 
them. He wrote letters to his dead friend that he read aloud in 
group. He was also very adept at helping others who had had 
similar experiences, and developed a career plan to one day 
be a counselor. His violent dreams faded with time, his rela-
tionship with his wife improved and he devoted himself to an 
exercise and nutrition regimen, quit smoking and began 
training with the goal of running the Marine Core Marathon 
in his friends honor. 
NEW DIAGNOSTIC OPPORTUNITIES 
  As discussed in this review, traumatic experiences can 
produce PTSD, a very debilitating condition. Unfortunately 
no biomarker except for the promise of genotyping for a 
validated PTSD gene panel to determine high risk [107] ex-
isted until most recently when Georgopoulos et al. [108] 
identified the synchronous neural interactions (SNI) test. SIN 
assesses the functional interactions among neural popula-
tions derived from magneticencephalographic (MEG) re-
cordings and can successfully differentiate PTSD patients 
from healthy control subjects. These new findings document 
robust differences in brain function between the PTSD and 
healthy controls. While we ponder the potential of pre-
existing genetic antecedents this work underscores differen-
tial diagnosis which possess the potential for screening and 
possibly monitoring disease progression and the effects of 
therapy. It is to be noted that one of us (ERB) has suggested 
that since the MEG is very expensive it should be appropri-
ate to diagnose PTSD and brain function with Brain Electro-
Activity Mapping (BEAM) in clinical primary care settings. 
It may be equally important to genotype PTSD patients for a 
number of neurotransmitter genes in conjunction with the 
BEAM test and or SNI.  
Treatment Goals 
  The prognosis for successful treatment of PTSD includes 
several factors beginning with the length of time that has 
passed since the trauma, as early intervention is effective in 
reducing symptoms and helping to prevent secondary 
chronic morbidity. The sufferer attitude to treatment, their 
capacity to tolerate distress, the availability of support and 
the extent of comorbidity are important factors.  
  The five main treatment goals are reducing the core 
symptoms, improving stress resilience, improving the quality 
of life, reducing disability and reducing comorbidity. Cogni-
tive behavioral therapy programs, exposure therapy and 
anxiety management are all employed, with the strongest 
evidence of success in exposure therapy. Anxiety manage-
ment techniques show good results after rape [109]. Alterna-
tive medicine is showing promise in the treatment of PTSD. 
Stress management techniques such as the deep relaxation 
response achieved through breathing techniques could be 
useful in controlling and/or responding to triggered alarm 
responses brought on by the recurrent memories. Aerobic 
exercise improves stamina, strength and general wellbeing 
and reduces aggressiveness. A study involving a group of 
PTSD veterans who practiced yoga exercises and meditation 
several times each day over six weeks produced a reduction 
in all symptoms and a general improvement in health and 
enthusiasm [110].  
  Other approaches might target the immune system since 
immunity is one of the areas directly affected in PTSD. Cir-
culating epinephrine and CRF are synergistic and act with 
cortisol to inhibit the function of the immune system [111].  
Enumerated Treatment Opportunities 
  In recent years the biologic origins of PTSD have been 
extensively researched and  there are basic conceptual re-
quirements that need to be addressed in a clinically accept-
able and scientifically sound paradigm shift in treating 
PTSD. Based on our current knowledge there are many tradi-
tional and non-traditional treatment opportunities  these in-
clude: 
-  Intervene early to reduce vulnerability by using genetic 
screening for and treatment with neuronutrient therapy 
both post disaster and abuse trauma and prior to military 
combat. 
-  Support resilience by the implementing interventions that 
result in strong social support for victims of disaster, war 
and abuse and by using cognitive behavioral therapy to 
develop; cognitive flexibility and a sense of mastery. 
-  Treat the symptoms of PTSD with cognitive therapy, 
behavioral techniques, stress reduction techniques and al-
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and integrate the traumatic event into the victim’s life. 
Use pharmacological and/or neuronutrient therapy for 
neurological symptoms of PTSD and comorbid psychiat-
ric illness including substances abuse disorder, anxiety, 
depression and psychosis. 
-  Treat reversible changes to the neuroanatomy of the brain 
pharmacologically and with brain training therapies. 
-  Early and vigorous treatment for physiological sequelae 
of chronic stress to reduce suffering, disability and cost. 
FUTURE PERSPECTIVE: UNDERSTANDING PTSD 
  PTSD may promote poor health through a complex inter-
action between biological and psychological mechanisms. 
Current thinking is that the experience of trauma brings 
about neurochemical changes in the brain. These changes 
may have biological, as well as psychological and behav-
ioral, effects on one's health. For example, these neuro-
chemical changes may create a vulnerability to hypertension 
and atherosclerosis heart disease that could explain in part 
the association with cardiovascular disorders. Research also 
shows that these neurochemical changes may relate to ab-
normalities in thyroid and other hormone functions, and to 
increased susceptibility to infections and immunologic dis-
orders associated with PTSD. The psychological and behav-
ioral effects of PTSD on health may be accounted for in part 
by co-morbid depressive and anxiety disorders. Many people 
with PTSD also experience depressive disorders or other 
disorders. Depressed individuals report a greater number of 
physical symptoms and use more medical treatment than do 
individuals who are not depressed. Depression also has been 
linked to cardiovascular disease in previously healthy popu-
lations and to additional illness and mortality among patients 
with serious medical illness [112]. Hostility, or anger, is an-
other possible mediator of the relationship between PTSD 
and physical health [25]. It is commonly associated with 
PTSD and decades of research on the health risks associated 
with the Type A behavior pattern have isolated hostility as a 
crucial factor in cardiovascular disease. A number of studies 
have found an association between PTSD and poor cardio-
vascular health. Among studies that have examined PTSD in 
relation to cardiovascular illness via self reporting of circula-
tory disorders, physician diagnosis or laboratory findings, 
PTSD has been consistently associated with a greater likeli-
hood of cardiovascular morbidity. PTSD and poor health 
also may be mediated in part by behavioral risk factors for 
disease such as smoking, substance abuse, diet, and lack of 
exercise. 
Proposal 
  It is our proposal that in order to successfully treat PTSD, 
each patient should be genetically tested prior to treatment 
and then by virtue of certain polymorphisms, target these 
resultant genetic deficiencies with compatable substances (i.e 
pharmacologic and or nutrients)-“body friendly” [16].  
HYPOTHESIS 
  Because genes contribute both to vulnerability and to 
resilience, we propose that successful treatment of PTSD 
will benefit from genetic testing prior to treatment. When 
certain polymorphisms are found, clinicians can target these 
resultant genetic deficiencies with compatible substances 
(i.e., pharmacological compounds and/or body friendly   
nutrients) [16]. In this regard, tests for the following genes 
are recommended: serotoninergic, dopaminergic (DRD2, 
DAT,DBH), glucocorticoid, GABAergic (GABRB), apol-
ipoprotein systems (APOE2), brain-derived neurotrophic 
factor, Monamine B, CNR1, Myo6, CRF-1 and CRF-2 re-
ceptors, and neuropeptide Y (NPY), Orexin and MCH. 
Treatment in part should be developed that would up-
regulate expression of these genes to bring about a feeling of 
well being, as well as a diminished recall of the traumatic 
event.  
  Early diagnosis is especially important. Thus, for combat 
related PTSD, we suggest that new military recruits be of-
fered the opportunity to be genetically tested for a predispo-
sition (vulnerability) to PTSD if it is likely that they will be 
exposed to multiple traumatic events. Understanding the 
extent of vulnerability through genetic testing prior to entry 
into the military might also prevent domestic violence by 
retuned PTSD soldiers following discharge [113]. The Army 
has declared soldiers' mental health a top priority [113], and 
it is our belief that screening soldiers for vulnerability to 
PTSD can decrease societal cost and individual victimiza-
tion. 
SUMMARY AND CONCLUSIONS 
  Trauma the stressor stimulates SNS via neurochemical 
messengers that include neurotransmitters and hormones. 
Genetic differences alter the impact of SNS stimulation on 
gene expression and results in resilience or vulnerability of 
individuals to PTSD. Particularly in vulnerable individuals 
the neurochemical response to stress, including alterations in 
the function of the neurotransmitters involved in both the 
response and connectivity of the mesolimbic system and the 
magnitude of the catecholamine response, results in the three 
categories of symptoms of PTSD; re-experiencing, avoid-
ance and increased arousal. The duration and extent of the 
cortisol response, causes alterations in neurophysiology that 
also support PTSD symptomatology. Untreated the symp-
toms of PTSD become a secondary stressor leading to the 
development of comorbidities. These include psychiatric 
disorders like depression and anxiety and the physiological 
symptoms of chronic stress including hypertension, heart 
disease, diabetes, gastrointestinal and musculoskeletal disor-
ders. In an attempt to ameliorate PTSD symptoms, sufferers 
become involved in substance abuse and other behaviors 
associated with Reward Deficiency Syndrome [76, 77], lead-
ing to social dysfunction for example homelessness among 
veterans, family breakup, loss of productivity and criminal-
ity. Additionally, as a result of the psychotic symptoms (for 
example, flashbacks, hyper-vigilance and paranoia) victims 
of PTSD become perpetrators of domestic violence. 
  Although the biological underpinnings of human re-
sponse to trauma are extremely complex, there are many 
points between the trauma and the development of PTSD 
symptomatology and comorbidities where interventions can 
be made to reduce morbidity and mortality. From this com-
prehensive review of the antecedents of PTSD, many areas 
for treatment with accepted modalities have been elucidated. Neuro-psychopharmacogenetics and Neurological Antecedents  Current Neuropharmacology, 2010, Vol. 8, No. 4    355 
Many more areas ripe for translational research have been 
identified. The understanding of the gene-environmental 
interactions will provide a diagnosis and treatment map to 
illuminate one’s vulnerability and or resilience for PTSD. We 
are suggesting that with new health legislation in USA that 
requires evidence based treatment, the wars in Afghanistan 
and Iraq, the global ecological crisis, and natural disasters, 
PTSD is a public health issue in need of urgent attention.  
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